从资金流向上来看，当日化学制药板块主力资金净流出11.08亿元，游资资金净流入5.65亿元，散户资金 净流入5.44亿元。化学制药板块个股资金流向见下表： 证券之星消息，10月9日化学制药板块较上一交易日下跌0.66%，南新制药领跌。当日上证指数报收于 3933.97，上涨1.32%。深证成指报收于13725.56，上涨1.47%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300584 | 海辰药业 | 63.81 | 13.76% | 15.58万 | 9.73亿 | | 300255 | 常山药业 | 49.29 | 8.21% | 39.44万 | 19.16亿 | | 600200 | *ST苏吴 | 1.00 | 5.26% | 48.36万 | 4553.49万 | | 603520 | 司太立 | 11.44 | 5.05% | 1 20.69万 | 2.38亿 | | 300705 | 九典制药 | 17.02 | 3.47% | 15.53万 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-40 河北常山生化药业股份有限公司 关于控股股东进行股票质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）近日接到控股股东高 树华先生函告，获悉高树华先生将其所持有本公司的部分股份进行质押，新增累 计质押股份数超过公司总股本的 5%。具体事项如下： 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | 累计质押 | 占其所 | 占公司 | 已质押股份情况 已质押股 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 （股） | 持股比例 | 股份数量 （股） | 持股份 比例 | 总股本 比例 | 份限售和 | 占已质 押股份 | 未质押股 份限售和 | 占未质 押股份 | | | | | | | | 冻结、标 记数量 | 比例 | 冻结数量 | 比例 | | 高树华 | 280,644 ...

2025年，河北常山生化药业股份有限公司2024年度股东大会通过议案，同意为全资子公司凯库得借款融 资提供不超3.6亿元担保额度，期限至2025年度股东大会。9月29日公告显示，公司于近日与农行正定县 支行签《保证合同》，为凯库得1366.25万元本金及利息提供连带责任保证，在已审议额度内无需再审 议。公告还披露凯库得基本情况、财务状况。截至公告日，公司及控股子公司担保额度206,000万元， 占最近一期经审计净资产131.86%；本次担保后，实际担保余额131,035.51万元，占比83.88%，无逾期 等异常担保情形。 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-39 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公 司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"）借款 融资提供不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起 至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供 担保额度预计的公告》（公告编号：2025-14）。 二、担保进展 2025 年 9 月 29 日，公司与中国农业银行股份有限公司正定县支行（以下简 称"农业银行"）签订了《保证合同》，公司为凯库得与农业银行签订的固定资 产借款合同下 1,366.25 万元的本金及利息提供连带责任保证。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 2．企业 ...

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.22%, reaching 46.80 CNY per share, with a trading volume of 677 million CNY and a turnover rate of 1.62%, resulting in a total market capitalization of 43.012 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products [1] - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Bosera Fund has a significant position in Changshan Pharmaceutical, with the Bosera National Index 2000 ETF holding 1,400 shares, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF, established on November 23, 2023, has a latest scale of 11.7815 million CNY and has achieved a year-to-date return of 38.28%, ranking 1165 out of 4220 in its category [2] - The fund manager, Tang Yibing, has a cumulative tenure of 3 years and 66 days, with the fund's total asset scale at 9.874 billion CNY, achieving the best return of 83.84% and the worst return of -41.93% during his tenure [2]

Group 1: Changshan Pharmaceutical - The company is preparing for clinical trials of Aibennate peptide for weight loss, with no current plans for oral formulation development [1] - Aibennate peptide is a long-acting GLP-1 receptor agonist, developed through chemical modification of exenatide [1] - The marketing preparation includes team building, product knowledge training, and marketing strategy formulation [1] Group 2: Fosun Pharma - Four innovative drugs approved in the first half of the year are expected to gradually increase sales in the coming months [2] - Innovative drug revenue exceeded 4.3 billion yuan, a year-on-year increase of 14.26%, accounting for over 30% of total drug revenue [2] - The company is actively participating in negotiations for the inclusion of its innovative drugs in insurance and national basic medical insurance directories [2] Group 3: Tiantan Biological Products - The company has established an international cooperation department to enhance its global market presence [3] - Products such as tetanus immunoglobulin and rabies immunoglobulin have already been exported [3] - The company is focused on international certification and registration of key products [3] Group 4: Kangtuo Medical - The US-based subsidiary BIOPLATE has launched a local production line for PEEK plates [4] - The company has completed market access in nearly 40 countries and regions [4] - The marketing of "4D bioactive plates" and PEEK fixation systems is underway in the US [4] Group 5: Tailong Pharmaceutical - The company is focusing on the development of modified new drugs across various therapeutic areas including respiratory, digestive, and oncology [5] - Projects in progress include treatments for Alzheimer's disease and schizophrenia [5] Group 6: Heng Rui Pharmaceutical - The HRS-5635 injection has been included in the list of proposed breakthrough therapies [6][7] - Chronic hepatitis B infection affects approximately 257 million people globally, with a significant mortality rate [7] - There is a pressing need for more effective treatments to achieve functional cure for chronic hepatitis B [7]

Market Overview - As of 10:30 AM, the Shanghai Composite Index is at 3827.97 points, with a decline of 0.10% [1] - The total trading volume of A-shares today is 113.62 billion yuan [1] Technical Analysis - A total of 162 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Changshan Pharmaceutical: 5-day MA is 1.52% lower than the 10-day MA [1] - Zero Point: 5-day MA is 1.19% lower than the 10-day MA [1] - Xiyu Co.: 5-day MA is 1.15% lower than the 10-day MA [1] Individual Stock Performance - Changshan Pharmaceutical (300255): Today's decline of 2.60%, with a 5-day MA of 47.08 yuan and a 10-day MA of 47.81 yuan, showing a distance of -1.52% [1] - Zero Point (301169): No change in price today, with a 5-day MA of 45.38 yuan and a 10-day MA of 45.92 yuan, showing a distance of -1.19% [1] - Xiyu Co. (000960): Today's increase of 1.22%, with a 5-day MA of 21.25 yuan and a 10-day MA of 21.50 yuan, showing a distance of -1.15% [1] Additional Stock Insights - ST Lifang (300344): Decline of 0.79%, with a 5-day MA of 5.15 yuan and a 10-day MA of 5.21 yuan, showing a distance of -1.08% [1] - Dongxin Peace (002017): Decline of 2.81%, with a 5-day MA of 26.14 yuan and a 10-day MA of 26.42 yuan, showing a distance of -1.06% [1] - Other stocks with notable performance include: - Yihua New Materials (301176): Decline of 0.87% [1] - Sanguang (002110): Decline of 0.71% [1]

Core Viewpoint - The company Changshan Pharmaceutical is facing multiple crises including financial deterioration, failed collective procurement, and high debt, challenging its aspirations for a turnaround through innovative drugs [2][3]. Financial Performance - In the first half of 2025, the company reported total revenue of 492 million yuan, a year-on-year decline of 13.42%, and a net profit attributable to shareholders of -29.09 million yuan [2]. - The company experienced a significant drop in second-quarter performance, with revenue decreasing nearly 10% quarter-on-quarter to 233 million yuan and a net profit loss of 32.87 million yuan, a staggering decline of 322.67% [4][5]. - The gross profit margin fell to 5% in the second quarter, marking a new low, and the overall gross profit margin for the first half of 2025 was 14.54%, down 8.28 percentage points year-on-year [6][8]. Business Segments - The company's main business remains heavily reliant on the heparin industry chain, with low molecular weight heparin preparations and heparin raw materials contributing 60.57% of total revenue [11]. - The revenue from low molecular weight heparin preparations was 204 million yuan, accounting for 41.46% of total revenue, but sales volume dropped by 19.17% year-on-year due to collective procurement policies [11][12]. Market Dynamics - The domestic heparin market is characterized by intense competition, with leading companies dominating the raw material export market, putting pressure on Changshan Pharmaceutical in the mid-to-low-end preparation market [13][14]. - The collective procurement policy has significantly reduced heparin preparation prices by over 50%, severely compressing profit margins for traditional product lines [14]. Innovation and R&D - The company’s R&D expenses decreased by 30.13% in the first half of 2025, primarily due to reduced direct investment in clinical trials for its drug Abenatide, which has faced delays in approval processes [17][18]. - The competitive landscape for GLP-1 drugs is intensifying, with several similar products already on the market, raising concerns about the differentiation and market potential of Changshan Pharmaceutical's Abenatide [18][19]. - The clinical progress of another innovative drug, CSCJC3456, has been slow, with the company still in the patient enrollment phase for its Phase I trial, lagging behind industry averages [19].

Core Viewpoint - The company is focusing on deepening its heparin business while also transitioning towards innovative drug development, particularly with the new drug Aibennate, which is in preparation for clinical trials [1] Group 1: Heparin Business - The company will continue to deepen its heparin business and promote the export of heparin preparations and raw materials [1] - The company aims to respond actively to changes in the domestic market and strives for the recovery and growth of heparin [1] Group 2: Innovative Drug Development - The company identifies innovative drugs as a key future development direction, pushing towards a transformation into an innovative drug enterprise [1] - Aibennate, a long-acting GLP-1 receptor agonist, is being prepared for weight loss clinical trials, with previous research data being utilized [1] - The marketing preparation for Aibennate includes team building, product knowledge training, and marketing plan formulation [1] Group 3: Clinical Trials and Regulatory Work - The first phase of clinical trials for Aibennate is in preparation and has not yet enrolled participants [1] - The company is working on supplementary technical documentation for Aibennate, which requires significant effort, aiming to complete it within the stipulated time [1] - The operational timeline of Changshan Kaijiejian does not affect the review process for Aibennate's market approval [1]

Group 1: Company Development and Strategy - The company will continue to focus on the heparin business, actively promoting the export of heparin preparations and raw materials, while flexibly responding to changes in the domestic market to achieve recovery and growth in the heparin business [1] - The company has identified innovative drugs as a key future development direction and is committed to transforming into an innovative drug enterprise [1] Group 2: Abebnate Progress and Sales Strategy - The submission of supplementary materials for Abebnate is a labor-intensive process and is not closely related to the issuance of the "Guidelines for the Clinical Trial of Recombinant Glucagon-like Peptide" [2] - The production capacity for Abebnate is currently over 20 million units annually, with the production facility previously built to meet the small-scale production needs for clinical trials [2] - The company is forming a marketing team for Abebnate and will gradually refine and adjust its marketing strategy based on the review progress and market conditions, but specific details cannot be disclosed at this time [2] Group 3: Other Relevant Issues - The technical cooperation with a U.S. company has not been affected by the political and economic situation, and the equity ratio of Changshan Kaijiejian remains unchanged during the renewal process [3] - The company currently has no specific plans for a targeted private placement, and the clinical trial for CSCJC3456 is ongoing, with no confirmed cancer type and no possibility of market launch in 2026 [3]